Evaluation of efficacy and safety of rebamipide use in the triple therapy for Helicobacter pylori eradication: a pilot study
https://doi.org/10.21518/2079-701X-2018-3-86-89
Abstract
The article presents the results of a pilot prospective randomized study aimed at evaluating the efficacy and safety of rebamipide (Rebagit, PRO.MED.CS Praha a.s., Czech Republic) as part of the triple therapy for helicobacter pylori (H. Pylori) eradication. 54 patients with H. pylori-associated gastric ulcer/duodenal ulcer were enrolled to the study. All patients were randomized to two therapeutic groups depending on the eradication therapy to be received. Group 1 received the standard triple therapy, Group 2 received the standard triple therapy plus rebamipide. The efficacy of H. pylori eradication in Group 1 amounted to 78,2% (ITT), 81,8% (PP), and in Group 2 to 83,8% (ITT), 86,6% (PP). Odd ratio of efficient eradication with the use of rebamipide as part of standard triple therapy for helicobacter pylori eradication was 1,44 (95 CI: 0,36–5,72). The side effect rates between the groups were comparable
About the Authors
D. T. Dicheva
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
D. N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
I. V. Partsvania-Vinogradova
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
Russian Federation
I. V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
Acad. of RAS, MD, Prof.
Russian Federation
Acad. of RAS, MD, Prof.
References
1. Chan FK, Lau J.Y. Peptic Ulcer Disease. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. 10th ed. 2015.
2. Maev IV, Samsonov AA, Andreev DN. Helico bacter pylori infection. Moscow: GEOTAR-Media, 2016.
3. Lanas A, Chan FK. Peptic ulcer disease. Lancet, 2017, 390(10094): 613-624.
4. Maev IV, Samsonov AA, Andreev DN. Gastric diseases. М.: GEOTAR-Media, 2015.
5. Morgan DR, Crowe SE. Helicobacter pylori infection. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management/edited by Mark Feldman, Lawrence S Friedman, Laurence J. Brandt. 10th ed. 2015.
6. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 2017, 66(1): 6-30.
7. Andreev D. Helicobacter pylori Eradication Therapy: Current Regimens. Adv Res Gastroentero Hepatol, 2017, 7(2): 555710.
8. Maev IV, Andreev DN, Samsonov AA, Veliev AM. Modern schemes of Helicobacter pylori eradication therapy: a strategy of differentiated use, efficacy and safety. Ekspe-rim. i klin. gastroenterol., 2017, 4 (140): 103-10
9. Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract, 2016, 2016: 9086581.
10. Andreev DN, Dicheva DT, Maev IV. Possibilities of optimization of Helicobacter pylori eradication therapy in modern clinical practice. Terapevticheskiy arkhiv, 2017, 2: 76-83
11. Kazyulin AN. The use of rebamipide as a gastroprotective and anti-inflammatory drug in the treat ment of peptic ulcer associated with Helico bacter pylori infection. Lechebnoe delo, 2016, 2: 51-57.
12. Andreev DN, Dicheva DT, Partzvania-Vinogradova EV. The use of rebamipide within the complex therapy of Helicobacter pylori-associated peptic ulcer of the stomach and duodenum: the systematization of literature data. Effektivnaya farmakoterapiya, 2017, 16: 34-36.
13. Iinuma S, Naito Y, Yoshikawa T, Takahashi S, Takemura T, Yoshida N, Kondo M. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci, 1998 Sep, 43(9 Suppl): 35S-39S.
14. Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M. Rebami pide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci, 1996, 41(6): 1139-44.
15. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol, 2010, 4(3): 261-70.
16. Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther, 2003, 18(Suppl 1): 153-9.
17. Kim CD, Kim YK, Lee SH, Hong KW. Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappaB-dependent pathway. J Pharmacol Exp Ther, 2000 Sep, 294(3): 864-9.
18. Lee KH, Kim JY, Kim WK, Shin DH, Choi KU, Kim DW, Lee WJ, Choi JH, Lee SH, Kim GH, Song GA, Jeon TY, Kim CD, Hong KW, Park DY. Protective effect of rebamipide against Helicobacter pylori-CagA-induced effects on gastric epithelial cells. Dig Dis Sci, 2011 Feb, 56(2): 441-8.
19. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol, 2014, 29(Suppl 4): 20-4.
20. Kuo CH, Lu CY, Shih HY et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol, 2014, 20(43): 16029-36.
21. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J, 2014, 30: 134-140.
22. Maev IV, Andreev DN. Molecular-genetic predictors of resistance to anti-Helicobacter therapy. Terapevticheskiy arkhiv, 2017, 89 (8): 5-12
23. Thung I, Aramin H, Vavinskaya V et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther, 2016, 43(4): 514-533.
24. Terano A, Arakawa T, Sugiyama T et al. Rebami pide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol, 2007, 42(8): 690-3.
25. Song KH, Lee YC, Fan DM et al. Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study. Digestion, 2011, 84(3): 221-9.
Review
For citations:
Dicheva DT, Andreev DN, Partsvania-Vinogradova IV, Maev IV. Evaluation of efficacy and safety of rebamipide use in the triple therapy for Helicobacter pylori eradication: a pilot study. Meditsinskiy sovet = Medical Council. 2018;(3):86-89. (In Russ.) https://doi.org/10.21518/2079-701X-2018-3-86-89
Views:
1364
Email this article 